Date published 
June 2012 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

Alzheimer’s Disease: Clinical Pipelines, R&D Challenges, and Future Directions - Table of Contents

 

Author: Mark C. Via

Executive Summary  

Chapter 1
Introduction
 

Chapter 2
Alzheimer’s Disease: Background and Pathology
2.1. Pathology of Alzheimer’s Disease
2.2. Causes of Alzheimer’s Disease
2.3. Diagnosis of Alzheimer’s Disease
2.4. Epidemiology of Alzheimer’s Disease
 

Chapter 3
Current Pharmacologic Treatment Options
3.1. Cholinesterase Inhibitors
Aricept (Donepezil HCl)
Exelon (Rivastigmine Tartrate)
Razadyne (Galantamine HBr)
3.2. NMDA Receptor AntagonistsNamenda (Memantine HCl)
3.3. Other Treatments 

Chapter 4
Compounds in Development: The Next Generation of Drugs for AD
4.1. Cholinergic Dysfunction
AstraZeneca/Targacept
EnVivo Pharmaceuticals
Abbott Laboratories
Anavex Life Sciences
4.2. Glutamatergic DysfunctionServier/Cortex Pharmaceuticals
AC Immune
Addex Therapeutics
4.3. Serotonergic DysfunctionNanotherapeutics
GlaxoSmithKline
Abbott Laboratories
Suven Life Sciences
Biotie Therapies/Roche
4.4. Histaminergic Dysfunction
4.5. Amyloid Cascade: Inhibiting Production
Bristol Myers-Squibb
Chiesi Farmaceutici
AC Immune
ExonHit Therapeutics
Sonexa Therapeutics
QR Pharma
Eisai
Noscira
Medisyn Technologies
Eli Lilly
Roche/Siena Biotech
Merck
EnVivo Pharmaceuticals
High Point Pharmaceuticals
Cellzome/Johnson & Johnson
NeuroGenetic Pharmaceuticals
Cortica Neurosciences
4.6. Amyloid Cascade: Stimulating RemovalPfizer/Johnson & Johnson
Eli Lilly
Roche/Genentech/AC Immune
Novartis/Cytos Biotechnology
AFFiRiS/GlaxoSmithKline
United Biomedical
Merck/Acumen Pharmaceuticals/Merz Pharma
BioArctic Neuroscience/Eisai
Biogen Idec/Neurimmune Therapeutics
Sanofi-Aventis
Boehringer Ingelheim/Ablynx
Intellect Neurosciences
Araclon Biotech
ArmaGen Technologies
TransTech Pharma
4.7. Amyloid Cascade: Preventing AggregationPrana Biotechnology
Bellus Health
Elan/Transition Therapeutics/Proteostasis Therapeutics
ProteoTech
Archer Pharmaceuticals
Probiodrug
D-Pharm
AC Immune
NeuroPhage Pharmaceuticals
Senexis
4.8. Tau PathologyTauRx Pharmaceuticals
Allon Therapeutics
Noscira
Bristol-Myers Squibb
Oligomerix
AC Immune
Intellect Neurosciences
Signum Biosciences/GlaxoSmithKline
4.9. NeuroprotectionNewron Pharmaceuticals
Roche/Evotec
4.10. NeurorestorationCeregene
NsGene
Enkam Pharmaceuticals
4.11. Cholesterol and Energy HomeostasisTakeda Pharmaceutical/Zinfandel Pharmaceuticals
Metabolic Solutions Development
Resverlogix
4.12. Second Messenger Modulation
4.13. Stem Cell Therapy
 

Chapter 5
Conclusion: Challenges and Future Directions
 

References 

Company Index